Key result
Ramipril reduces CV events and target organ damage in high-risk hypertension via vasculoprotective and renoprotective effects.
Why the study?
Available data on ramipril in hypertensive patients of high cardiovascular risk needed summarization to clarify its clinical benefits and safety.
Does ramipril improve cardiovascular and renal outcomes in hypertensive patients of high cardiovascular risk?
Does ramipril improve cardiovascular and renal outcomes in hypertensive patients of high cardiovascular risk?
Ramipril is an effective and well-tolerated therapy that provides cardiovascular, renal, and vascular protection in high-risk hypertensive and diabetic patients.
May support ramipril consideration in high-risk hypertension; leaves open need for updated randomized confirmation.
The article summarizes the available data on ramipril in hypertensive patients of high cardiovascular risk. The results of studies demonstrate strong and long-lasting antihypertensive effect of ramipril. Moreover, ramipril treatment decreases cardiovascular events rate, damage of target organs, atherosclerosis progression and new cases of diabetes mellitus. The treatment by ramipril represents vasculoprotective and renoprotective effects in diabetes patients. Possible antiarrhythmic activity of ramipril is of particular interest in atrial fi brillation. Ramipril shows both high effi cacy and low adverse event rate. All this properties make ramipril extremely attractive for the everyday practice.
No takes yet. Share an insight, caveat, or question.
Гончарова et al. (2009) conducted a review in Hypertension with high cardiovascular risk. Ramipril was evaluated. Ramipril demonstrates strong antihypertensive, vasculoprotective, and renoprotective effects, decreasing cardiovascular events and target organ damage in high-risk hypertensive patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: